4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Update

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 8,520,000 shares, an increase of 8.8% from the November 15th total of 7,830,000 shares. Based on an average trading volume of 894,400 shares, the short-interest ratio is currently 9.5 days.

4D Molecular Therapeutics Trading Down 1.5 %

Shares of NASDAQ:FDMT traded down $0.10 on Tuesday, reaching $6.38. 169,420 shares of the company’s stock were exchanged, compared to its average volume of 882,602. The company has a fifty day moving average of $8.03 and a 200-day moving average of $14.34. 4D Molecular Therapeutics has a twelve month low of $6.31 and a twelve month high of $36.25. The company has a market capitalization of $294.93 million, a price-to-earnings ratio of -2.24 and a beta of 2.74.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Principal Financial Group Inc. grew its position in shares of 4D Molecular Therapeutics by 9.6% during the 2nd quarter. Principal Financial Group Inc. now owns 21,034 shares of the company’s stock worth $442,000 after purchasing an additional 1,849 shares in the last quarter. Algert Global LLC boosted its position in shares of 4D Molecular Therapeutics by 20.6% during the 2nd quarter. Algert Global LLC now owns 16,588 shares of the company’s stock worth $348,000 after acquiring an additional 2,828 shares in the last quarter. nVerses Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics during the 3rd quarter worth approximately $40,000. The Manufacturers Life Insurance Company boosted its position in shares of 4D Molecular Therapeutics by 25.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,975 shares of the company’s stock worth $398,000 after acquiring an additional 3,850 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of 4D Molecular Therapeutics by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after acquiring an additional 3,922 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. Leerink Partners reiterated an “outperform” rating and issued a $36.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Chardan Capital restated a “buy” rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. Finally, Royal Bank of Canada lowered their price objective on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and an average target price of $42.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.